Observational studyPloS one2018
Long term outcomes after left atrial appendage closure with the LARIAT device-Stroke risk reduction over five years follow-up.
Observational study in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Between a Rock and a Hard Place: Balancing Embolic Stroke and Intracerebral Hemorrhage Risk in Left Atrial Appendage Occlusion.Journal of cardiovascular development and disease · 2026Review
- Anti-amyloid treatment in Alzheimer disease: updated implications for patients with cerebral amyloid angiopathy and other cerebrovascular conditions.Frontiers in neurology · 2026Review
- Simultaneous Endocardial and Epicardial Approach for Successful Closure of Left Atrial Appendage With Difficult Anatomy.JACC. Case reports · 2025Article
- Cerebrovascular Management Considerations in Patients on AATs.Journal of clinical medicine · 2025Review
- Device-Assisted Left Atrial Appendage Exclusion: From Basic Sciences to Clinical Applications.Journal of cardiovascular development and disease · 2024Review
- Lower-adherence direct oral anticoagulant use is associated with increased risk of thromboembolic events than warfarin.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2024Article
- Article
- A decade later: long-term results of the first percutaneous epicardial closure of the left atrial appendage using the LARIAT device.Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery · 2023Article
- Heart Team for Left Appendage Occlusion without the Use of Antithrombotic Therapy: The Epicardial Perspective.Journal of clinical medicine · 2022Article
- Changes in fibrinolytic activity and coagulation factors after epicardial left atrial appendage closure in patients with atrial fibrillation.Journal of thoracic disease · 2022Article
- Article
- Percutaneous Treatment Approaches in Atrial Fibrillation: Current Landscape and Future Perspectives.Biomedicines · 2022Review
- Review
- Long-term effect of anticoagulation following left atrial appendage occlusion with the LARIAT device in patients with nonvalvular atrial fibrillation: impact on thromboembolism, bleeding and mortality. Real life data.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2020Article
- Evaluation of Local Tissue Reaction After the Application of a 3D Printed Novel Holdfast Device for Left Atrial Appendage Exclusion.Annals of biomedical engineering · 2020Article
- Percutaneous left atrial appendage closure using the LAmbre device. First clinical results in Poland.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLeft atrial appendage closure (LAAC) with LARIAT offers an alternative to oral anticoagulation (OAC) for patients with atrial fibrillation. The aim of this study was to present long-term clinical outcomes of LAAC in these patients (AF). MATERIAL AND
methodsA prospective, single-center study was performed in 139 patients undergoing LAAC with Lariat. Thromboembolic events, severe bleeding and mortality rate were recorded. The reduction in risk of thromboembolism and bleeding after LAAC was calculated.
resultsThe mean CHADS2-score was 1.8 ± 1.0, mean CHA2DS2-VASc score was 2.9 ± 1.6 and HAS-BLED score was 3.1 ± 1.1. After 428.4 patient-years of follow-up (mean 4.2±1.0 years), the thromboembolism rate was 0.6% with a calculated thromboembolism risk reduction of 81%. The severe bleeding rate was 0.8%; calculated bleeding risk reduction was 78%. The overall mortality rate was 1.6%.
conclusionsLong-term outcomes show that LAAC with Lariat is a safe and effective treatment for stroke prevention and bleeding risk reduction in AF patients with a high level of underlying risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.